Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H7O3.Na |
Molecular Weight | 174.1291 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC1=CC=CC(C([O-])=O)=C1O
InChI
InChIKey=ODAXNLPYGWAGTH-UHFFFAOYSA-M
InChI=1S/C8H8O3.Na/c1-5-3-2-4-6(7(5)9)8(10)11;/h2-4,9H,1H3,(H,10,11);/q;+1/p-1
Molecular Formula | C8H7O3 |
Molecular Weight | 151.1394 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Hydroxytoluic acid is a long-acting derivative of salicylate with antilipidemic properties. It shows fibrinolytic activity in human plasma by activating the fibrinolytic system and has been shown to lower plasma free fatty acid, cholesterol levels, and to raise metabolic oxygen consumption.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4932011
Diabetic geriatric patients received 900 mg Hydroxytoluic acid orally as a single dose or as a daily dose of up to 2.7g/day for 3 months. For patients receiving a single dose a 50 g glucose tolerance test was performed 2 hours after dosing, for longitudinal patients the glucose tolerance test was performed monthly or every two months. After a single 900 mg dose, plasma insulin levels showed considerable increases, plasma free fatty acid fell 2 hours after dosing with hydroxytoluic acid. Daily dosing of 1.8 g/day hydroxytoluic acid as the sole treatment allowed patients to control their diabetes but was not significantly different from controls. When added to the existing drug regimen patients receiving hydroxy toluic acid showed a smoothing of control of blood sugar with decreased needs of insulin or sulphonylurea.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:31:43 GMT 2023
by
admin
on
Sat Dec 16 12:31:43 GMT 2023
|
Record UNII |
2Y32FEU3GB
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
251-202-2
Created by
admin on Sat Dec 16 12:31:43 GMT 2023 , Edited by admin on Sat Dec 16 12:31:43 GMT 2023
|
PRIMARY | |||
|
2Y32FEU3GB
Created by
admin on Sat Dec 16 12:31:43 GMT 2023 , Edited by admin on Sat Dec 16 12:31:43 GMT 2023
|
PRIMARY | |||
|
32768-20-0
Created by
admin on Sat Dec 16 12:31:43 GMT 2023 , Edited by admin on Sat Dec 16 12:31:43 GMT 2023
|
PRIMARY | |||
|
DTXSID20186431
Created by
admin on Sat Dec 16 12:31:43 GMT 2023 , Edited by admin on Sat Dec 16 12:31:43 GMT 2023
|
PRIMARY | |||
|
23668291
Created by
admin on Sat Dec 16 12:31:43 GMT 2023 , Edited by admin on Sat Dec 16 12:31:43 GMT 2023
|
PRIMARY |